← Latest briefing

Health

Viagra-like tablet AR1001 slows decline in some early Alzheimer's patients, trial suggests

The Guardian reports a 31% slowing of decline in untreated patients, while the wider trial group showed no significant benefit.

The short version

  • The Guardian reports that a 13-country stage three trial found the tablet AR1001 slowed decline by 31% in early Alzheimer's patients not receiving other treatments.[The Guardian]
  • AriBio, the South Korean company that makes AR1001, said the drug slowed decline in 604 people taking no other Alzheimer's drugs.[The Guardian]
  • In a wider group taking other Alzheimer's drugs, the benefit was not statistically significant.[The Guardian]
  • Independent experts called the results promising but said further trials and regulatory scrutiny are needed before prescribing.[The Guardian]

Key facts

  • A global stage three trial across 13 countries reported that AR1001 slowed cognitive decline by 31% in early Alzheimer's patients not receiving other treatments.[The Guardian]
  • AriBio, the South Korean company that makes AR1001, said the drug slowed decline in 604 people taking no other Alzheimer's drugs.[The Guardian]
  • In a wider group of patients taking other Alzheimer's drugs, the tablet did not achieve statistically significant results.[The Guardian]
  • Experts not involved in the study called the results promising but said further trials and regulatory scrutiny are needed before prescribing.[The Guardian]
  • AR1001 is from the same family of medicines as Viagra but is being developed specifically for Alzheimer's disease.[The Guardian]

What remains uncertain

  • The 31% slowing applies to a subgroup not taking other Alzheimer's drugs; the benefit was not statistically significant in the wider group taking other drugs.[The Guardian]
  • The 604-patient figure comes from AriBio, the company that makes the drug, and has not been independently verified in the reporting.[The Guardian]
  • Experts called for further trials and regulatory review, and it is unknown whether AR1001 will be approved for Alzheimer's treatment.[The Guardian]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.